DaunoXome data

Researchers presented data from a Phase II study in 18 patients with relapsed and resistant lymphomas. In the study, 8 patients received 120 mg/m2 of DaunoXome every 21 days, and 10 patients were given 40 mg/m2 every 14 days. ...